Humanigen, Inc. Receives Preliminary Topline Data from NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B

Humanigen, Inc. has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases' ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus... | July 13, 2022

Related Keywords

,National Institutes Of Health ,Humanigen Inc ,National Institute Of Allergy ,National Institute ,Infectious Disease ,National Institutes ,Big Effect Trial ,Humanigen ,Nc Stock Exchange ,News ,Information ,Press Release ,Gas ,Teen ,Nformed ,F ,Reliminary ,Topline ,Results ,Rom ,The ,Ational ,Institute ,Allergy ,End ,Nfectious ,Trial ,Valuating ,Lenzilumab ,Plus ,Emdesivir Hgen Us4448632038 ,